Partnerships and Licensing

AuraSense is using its proprietary SNA technology platform to build a broad pipeline of products for a range of diseases with unmet medical need.  The company's strategy is to maximize the potential of its Spherical Nucleic Acid (SNA) technology platform through in-house development, collaborations and licensing.

AuraSense may also establish platform partnerships with pharmaceutical companies across multiple indications or within specific therapeutic areas.

For more information regarding AuraSense's partnering strategy, please contact Gordon Beck, Ph.D., VP Business Development, gbeck at aurasense.com.

Latest News

  • David Giljohann Named Among Top 40 Under 40 by Analytical Scientist

    October 29, 2014go

  • Google’s Newest Search: Cancer Cells

    October 28, 2014go

  • AuraSense Therapeutics Expands Leadership Team

    October 1, 2014go

  • AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer

    July 23, 2014go

  • Bill Gates among new backers of Skokie startup

    June 20, 2014go